Of these, the vast majority were IDH-wildtype infiltrating astrocytoma (67/77; 87.0%) with IDH mutant infiltrating astrocytoma being the second most common tumor type for which CDKN2A loss was detected by targeted NGS (5/77; 6.5%). This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).